Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plasma-Lyte A + Autologous Plasma is a combination solution used primarily as a vehicle for cell therapy or as a placebo control in clinical research. It consists of Plasma-Lyte A, a balanced crystalloid solution manufactured by Baxter, and plasma derived from the patient's own blood. This specific combination was utilized as the placebo arm in the Phase IIb Enhanced Angiogenic Cell Therapy (EACT) trial (NCT00874445), led by the Ottawa Hospital Research Institute, which evaluated the transplantation of autologous endothelial progenitor cells (EPCs) for the treatment of acute myocardial infarction. The solution provides a pH-balanced, isotonic electrolyte environment supplemented with autologous proteins to maintain cell viability during delivery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Plasma-Lyte A + autologous plasma.